Syndromic Craniosynostosis is an unmet medical need, and over 80% of them are caused by mutations in Fibroblast Growth Factor Receptor 2 (FGFR2) gene.

Krouzon Pharmaceuticals is developing pharmacological treatments for the following most common FGFR2-related Syndromic Craniosynostosis:

• Pfeiffer syndrome

• Apert syndrome

• Crouzon syndrome

The developmental disorders of Syndromic Craniosynostosis include anatomical, physiological, neurological, and psychological disorders as described below:

1. ANATOMICAL DISORDERS:

   • Severe Deformity of head and face

2. PHYSIOLOGICAL AND NEUROLOGICAL DISORDERS:

   • Developmental delay

   • Vision disorders

   • Hearing loss (70% cases)

   • Difficulty in breathing

   • Sleep apnea

   • Gastrointestinal disorders

   • Precocious puberty

   • Seizures

   • Death in severe cases

3. PSYCHOLOGICAL IMPACT:

   • Children experience lifelong social isolation